🎉 M&A multiples are live!
Check it out!

ProQR Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for ProQR Therapeutics and similar public comparables like Galapagos, Pharming, and Benevolent AI.

ProQR Therapeutics Overview

About ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.


Founded

2012

HQ

United States of America
Employees

166

Website

proqr.com

Financials

LTM Revenue $24.8M

LTM EBITDA -$23.5M

EV

-$26.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ProQR Therapeutics Financials

ProQR Therapeutics has a last 12-month revenue of $24.8M and a last 12-month EBITDA of -$23.5M.

In the most recent fiscal year, ProQR Therapeutics achieved revenue of $18.9M and an EBITDA of -$24.1M.

ProQR Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ProQR Therapeutics valuation multiples based on analyst estimates

ProQR Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.5M $18.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$24.1M -$24.1M XXX XXX XXX
EBITDA Margin -370% -128% XXX XXX XXX
Net Profit -$65.1M -$28.1M XXX XXX XXX
Net Margin -1000% -149% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ProQR Therapeutics Stock Performance

As of April 15, 2025, ProQR Therapeutics's stock price is $1.

ProQR Therapeutics has current market cap of $124M, and EV of -$26.0M.

See ProQR Therapeutics trading valuation data

ProQR Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$26.0M $124M XXX XXX XXX XXX $-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ProQR Therapeutics Valuation Multiples

As of April 15, 2025, ProQR Therapeutics has market cap of $124M and EV of -$26.0M.

ProQR Therapeutics's trades at -1.1x LTM EV/Revenue multiple, and 1.2x LTM EBITDA.

Analysts estimate ProQR Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ProQR Therapeutics and 10K+ public comps

ProQR Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$26.0M XXX XXX XXX
EV/Revenue -1.4x XXX XXX XXX
EV/EBITDA 1.1x XXX XXX XXX
P/E -4.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ProQR Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ProQR Therapeutics Valuation Multiples

ProQR Therapeutics's NTM/LTM revenue growth is 20%

ProQR Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, ProQR Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ProQR Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ProQR Therapeutics and other 10K+ public comps

ProQR Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 190% XXX XXX XXX XXX
EBITDA Margin -128% XXX XXX XXX XXX
EBITDA Growth 0% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -108% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 72% XXX XXX XXX XXX
R&D Expenses to Revenue 192% XXX XXX XXX XXX
Opex to Revenue 261% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ProQR Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ProQR Therapeutics M&A and Investment Activity

ProQR Therapeutics acquired  XXX companies to date.

Last acquisition by ProQR Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . ProQR Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ProQR Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ProQR Therapeutics

When was ProQR Therapeutics founded? ProQR Therapeutics was founded in 2012.
Where is ProQR Therapeutics headquartered? ProQR Therapeutics is headquartered in United States of America.
How many employees does ProQR Therapeutics have? As of today, ProQR Therapeutics has 166 employees.
Who is the CEO of ProQR Therapeutics? ProQR Therapeutics's CEO is Mr. Daniel de Boer.
Is ProQR Therapeutics publicy listed? Yes, ProQR Therapeutics is a public company listed on NAS.
What is the stock symbol of ProQR Therapeutics? ProQR Therapeutics trades under PRQR ticker.
When did ProQR Therapeutics go public? ProQR Therapeutics went public in 2014.
Who are competitors of ProQR Therapeutics? Similar companies to ProQR Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ProQR Therapeutics? ProQR Therapeutics's current market cap is $124M
What is the current revenue of ProQR Therapeutics? ProQR Therapeutics's last 12-month revenue is $24.8M.
What is the current EBITDA of ProQR Therapeutics? ProQR Therapeutics's last 12-month EBITDA is -$23.5M.
What is the current EV/Revenue multiple of ProQR Therapeutics? Current revenue multiple of ProQR Therapeutics is -1.1x.
What is the current EV/EBITDA multiple of ProQR Therapeutics? Current EBITDA multiple of ProQR Therapeutics is 1.2x.
What is the current revenue growth of ProQR Therapeutics? ProQR Therapeutics revenue growth between 2023 and 2024 was 190%.
Is ProQR Therapeutics profitable? Yes, ProQR Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.